Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro
Authors:
- J.M. NakashimaJNJ.M. Nakashima
- L. FengLFL. Feng
- S.N. GiriSGS.N. Giri
- S.B. MargolinSMS.B. Margolin
- 1 May 2008
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 8 (5) , 679-687
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administrationBiopharmaceutics & Drug Disposition, 2002
- Pirfenidone Blocks the In Vitro and In Vivo Effects of Staphylococcal Enterotoxin BInfection and Immunity, 2002
- Pirfenidone for chronic progressive multiple sclerosisMultiple Sclerosis Journal, 2001
- TUMOR NECROSIS FACTOR RECEPTOR AND Fas SIGNALING MECHANISMSAnnual Review of Immunology, 1999
- Membrane Tumor Necrosis Factor-α (TNF-α) Expressed on HTLV-I-Infected T Cells Mediates a Costimulatory Signal for B Cell Activation—Characterization of Membrane TNF-αClinical Immunology and Immunopathology, 1997
- Cytokines in inflammatory brain lesions: helpful and harmfulTrends in Neurosciences, 1996
- Two tumour necrosis factor receptors: structure and functionTrends in Cell Biology, 1995
- Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.Journal of Clinical Investigation, 1994
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992
- Tumor Necrosis Factor (TNF)Science, 1985